Business & Industry

AbbVie and Iambic have entered into a multiyear collaboration focused on AI drug discovery across three major therapeutic areas — immunology, neuroscience, and oncology. The partnership brings together Iambic's molecular superintelligence platform and AbbVie's established drug discovery expertise, with...

Neuraxpharm and Minoryx Therapeutics have secured European Commission approval for Nezglyal (leriglitazone), making it the first approved drug therapy for rare disease cALD — cerebral adrenoleukodystrophy — in the European Union, with a commercial launch expected before the end...

A United States Food and Drug Administration advisory panel has voted in favour of approving GRAIL's Galleri, positioning the multi-cancer early detection test for a potential landmark regulatory decision in the months ahead. Panel Votes Across Three Key Dimensions The ten...

Chinese biopharmaceutical company InnoCare Pharma has entered into a strategic research collaboration and licensing agreement with Eli Lilly and Company to develop new medicines, with total potential payments reaching approximately $3.35 billion. Agreement Structure and Financial Terms Under the terms of...

Novartis has entered into an exclusive global license agreement with BoomRay Pharmaceuticals for an undisclosed preclinical radioligand therapy asset, with total potential payments to BoomRay reaching up to $900 million. Announced on September 22, 2026, this radioligand license deal brings...

The UK's National Institute for Health and Care Research (NIHR) has opened the first funding round for its Strategic Infrastructure Partnerships programme, inviting applications for a share of £45 million aimed at accelerating the translation of early-stage medical discoveries...

Obesity treatment is entering a more competitive phase. Ozempic and Mounjaro helped make GLP-1-based medicines mainstream, but the next wave is looking beyond simply producing weight loss. The opportunity is significant because obesity remains widespread. U.S. data show that 40.3%...